STOCKHOLDERS’ DEFICIT (Tables)

6 Months Ended

Sep. 30, 2025

SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS, ACTIVITY

The following is an analysis of the stock option grant activity under the Plan:

	Number		Weighted Average Exercise Price		Weighted Average Remaining Life
Stock Options
Outstanding March 31, 2025		136,183	$	3.72		5.53
Granted		-		-		-
Expired		-		-		-
Exercised		-		-		-
Outstanding September 30, 2025		136,183	$	3.72		5.04

SCHEDULE OF SHARE-BASED COMPENSATION NONVESTED SHARES

A summary of the status of the Company’s nonvested options as of September 30, 2025, and changes during the six months ended September 30, 2025 is presented below:

Nonvested Options	Options			Weighted- Average Exercise Price
Nonvested at March 31, 2025		35,123		$	3.72
Granted		-			-
Vested		(9,056	)		3.72
Forfeited		-			-
Nonvested at September 30, 2025		26,067		$	3.17

SUMMARY OF WARRANT

A summary of warrant issuances are as follows:

SUMMARY OF WARRANT

	Number			Weighted Average Exercise Price		Weighted Average Remaining Life
Warrants

Outstanding March 31, 2025		4,620,192		$	221.32		1.49
Granted		719,056			3.65		-
Expired		(1,458	)		70.00		-
Exercised		(1,374,904	)		112.42		-
Outstanding September 30, 2025		3,962,886		$	267.55		0.66

Protagenic Therapeutics, Inc.\new 10-Q